KZIA vs. LGVN, NAII, MTEX, ATHE, CDIO, EQ, DRRX, ENLV, LPCN, and MRKR
Should you be buying Kazia Therapeutics stock or one of its competitors? The main competitors of Kazia Therapeutics include Longeveron (LGVN), Natural Alternatives International (NAII), Mannatech (MTEX), Alterity Therapeutics (ATHE), Cardio Diagnostics (CDIO), Equillium (EQ), DURECT (DRRX), Enlivex Therapeutics (ENLV), Lipocine (LPCN), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical products" industry.
Kazia Therapeutics vs.
Longeveron (NASDAQ:LGVN) and Kazia Therapeutics (NASDAQ:KZIA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, community ranking, valuation, risk and analyst recommendations.
10.0% of Longeveron shares are held by institutional investors. Comparatively, 30.9% of Kazia Therapeutics shares are held by institutional investors. 19.1% of Longeveron shares are held by company insiders. Comparatively, 1.0% of Kazia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Kazia Therapeutics has higher revenue and earnings than Longeveron.
Kazia Therapeutics received 63 more outperform votes than Longeveron when rated by MarketBeat users. However, 94.12% of users gave Longeveron an outperform vote while only 52.67% of users gave Kazia Therapeutics an outperform vote.
In the previous week, Kazia Therapeutics had 1 more articles in the media than Longeveron. MarketBeat recorded 1 mentions for Kazia Therapeutics and 0 mentions for Longeveron. Longeveron's average media sentiment score of 1.00 beat Kazia Therapeutics' score of 0.50 indicating that Longeveron is being referred to more favorably in the media.
Kazia Therapeutics has a net margin of 0.00% compared to Longeveron's net margin of -967.49%. Kazia Therapeutics' return on equity of 0.00% beat Longeveron's return on equity.
Longeveron currently has a consensus price target of $8.67, suggesting a potential upside of 392.42%. Kazia Therapeutics has a consensus price target of $20.00, suggesting a potential upside of 1,323.49%. Given Kazia Therapeutics' higher probable upside, analysts plainly believe Kazia Therapeutics is more favorable than Longeveron.
Longeveron has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Kazia Therapeutics has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500.
Summary
Kazia Therapeutics beats Longeveron on 10 of the 17 factors compared between the two stocks.
Get Kazia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kazia Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:KZIA) was last updated on 1/21/2025 by MarketBeat.com Staff
